White Papers
Ketoprofen
FDA says NSAIDS increase risk of heart attack
Date: 09.27.2021
Date: 02.11.2019
Gabapentin
Plasma concentration of oral gabapentin dose not increase proportionally with increase dosing
Date: 04.12.21
Why Gabapentin may become a Schedule V controlled substance
Date: 01.30.2020
Topical Gabapentin use on CRPS
Date: 10.29.2019
Date: 10.09.2017
Naltrexone
Focus: Addiction drug shows promise lifting long COVID brain fog, fatigue
Date: 10.18.2022
CHICAGO, Oct 18 (Reuters) - Lauren Nichols, a 34-year-old logistics expert for the U.S. Department of Transportation in Boston, has been suffering from impaired thinking and focus, fatigue, seizures, headache and pain since her COVID-19 infection in the spring of 2020. Last June, her doctor suggested low doses of naltrexone, a generic drug typically used to treat alcohol and opioid addiction. After more than two years of living in "a thick, foggy cloud," she said, "I can actually think clearly." (Read more...)
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
Date: 10.24.2022
Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. LDN is safe in patients with PCS and may improve well-being and reduce symptomatology in this cohort. Randomised control trials are needed to further explore this. (Read more...)
Low-Dose Naltrexone Could Treat Long COVID Symptoms
Date: 6.7.2023
Naltrexone is a drug approved by the Food and Drug Administration (FDA) to treat alcohol use disorder and opioid addiction. Low-dose naltrexone (LDN), usually at a fraction of the regular dose, has been used to treat fibromyalgia and multiple sclerosis. (Read more...)